House bars registrants from knowingly supplying drugs or devices for executions

The House passed substitute House Bill 5225 on Monday, making it unlawful for Connecticut registrants to knowingly sell drugs or devices that will be used to carry out a court-imposed death sentence in another jurisdiction.

Representative Curtis Lamar described the bill as a narrow measure reflecting the states longstanding position against capital punishment and as a way to prevent Connecticut-based manufacturers and distributors from facilitating executions elsewhere. "This ensures that moving forward, no person, entity or business can manufacture, sell, dispense, transfer, deliver any drug or device if they know it will be used to carry out a death sentence," Lamar said on the floor.

Members pressed the sponsor on definitions and enforcement. Lawmakers asked for clarity on who counts as a "registrant," what constitutes a "device," and how "actual knowledge" would be proved. Representative Elias Dubinsky raised scenarios involving intermediate distributors and whether a manufacturer who sells to a middleman would face liability if the product is later used in an execution.

The bill does not ban the manufacture of drugs or devices generally; instead it creates a narrow criminal and civil prohibition tied to knowledge that a sale is intended for carrying out a death sentence. Penalties in the text include fines and, in certain narrow circumstances, imprisonment; sponsors emphasized the statutory standard requires actual knowledge.

The House approved the substitute by roll call. Supporters said the change harmonizes Connecticut policy with the states opposition to capital punishment and prevents out-of-state executions from being supported by Connecticut-sourced supplies. Detractors urged tighter drafting to avoid unintended consequences for ordinary manufacturers and distributors whose products are not designed for execution use.

Next steps: the bill will proceed to the Senate. Sponsors and critics said further statutory refinement could be considered to clarify registrant scope and penalties.